InvestorsObserver
×
News Home

How Will the Market React to I-Mab ADR (IMAB) Stock Getting a Bearish Rating

Tuesday, January 24, 2023 01:03 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to I-Mab ADR (IMAB) Stock Getting a Bearish Rating

I-Mab ADR (IMAB) stock is lower by 2.19% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
I-Mab ADR has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IMAB!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IMAB Stock Today?

I-Mab ADR (IMAB) stock is trading at $6.70 as of 1:02 PM on Tuesday, Jan 24, a drop of -$0.05, or -0.74% from the previous closing price of $6.75. The stock has traded between $6.60 and $7.17 so far today. Volume today is low. So far 180,893 shares have traded compared to average volume of 823,734 shares. To see InvestorsObserver's Sentiment Score for I-Mab ADR click here.

More About I-Mab ADR

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature. Click Here to get the full Stock Report for I-Mab ADR stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App